Compare · ECOR vs ITGR
ECOR vs ITGR
Side-by-side comparison of electroCore Inc. (ECOR) and Integer Holdings Corporation (ITGR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ECOR and ITGR operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- ITGR is the larger of the two at $3.10B, about 37.7x ECOR ($82.4M).
- ITGR has been more active in the news (16 items in the past 4 weeks vs 6 for ECOR).
- ITGR has more recent analyst coverage (23 ratings vs 2 for ECOR).
- Company
- electroCore Inc.
- Integer Holdings Corporation
- Price
- -
- -
- Market cap
- $82.4M
- $3.10B
- 1M return
- +50.76%
- -
- 1Y return
- +77.36%
- -
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NYSE
- IPO
- 2018
- News (4w)
- 6
- 16
- Recent ratings
- 2
- 23
electroCore Inc.
electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld delivery system for multi-year use prescribed on a monthly basis. The company was founded in 2005 and is headquartered in Rockaway, New Jersey.
Integer Holdings Corporation
Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates in two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology procedures. It also provides cardiac rhythm management products, including implantable pacemakers, implantable cardioverter defibrillators, insertable cardiac monitors, implantable cardiac pacing and defibrillation leads, and heart failure therapies; neuromodulation products, such as implantable spinal cord stimulators; and non-rechargeable batteries, feedthroughs, device enclosures, machined components, and lead components and sub-assemblies. In addition, the company offers rechargeable batteries and chargers; and arthroscopic, laparoscopic, and general surgery devices and components, such as harmonic scalpels, shaver blades, burr shavers, radio frequency probes, biopsy probes, trocars, electrocautery components, wound dressings, GERD treatment components, and phacoemulsification needles. Further, it provides orthopedic products that include instruments used in hip, knee, and spine surgeries, as well as reamers and chisels. Additionally, the company offers customized battery power and management systems, charging and docking stations, and power supplies for the energy, military, and environmental markets. It serves multi-national original equipment manufacturers and their affiliated subsidiaries in the cardiac, neuromodulation, orthopedics, vascular, and advanced surgical and portable medical markets. The company was formerly known as Greatbatch, Inc. and changed its name to Integer Holdings Corporation in July 2016. Integer Holdings Corporation was founded in 1970 and is headquartered in Plano, Texas.
Latest ECOR
- Frontiers in Neuroscience Accepts Review Article Synthesizing Evidence that Cervical nVNS Activates the Vagus Nerve Without Surgery
- electroCore to Present at the Planet MicroCap Las Vegas 2026 Powered by MicroCapClub
- CFO and Interim President Lev Joshua S. sold $60,003 worth of shares (6,667 units at $9.00), decreasing direct ownership by 7% to 84,889 units (SEC Form 4)
- SEC Form 144 filed by electroCore Inc.
- Director Errico Thomas J. bought $59,852 worth of shares (9,992 units at $5.99), increasing direct ownership by 3% to 360,071 units (SEC Form 4)
- CFO and Interim President Lev Joshua S. sold $19,500 worth of shares (3,000 units at $6.50), decreasing direct ownership by 3% to 91,556 units (SEC Form 4) (tax liability)
- SEC Form 144 filed by electroCore Inc.
- electroCore Announces Publication in JAMA Highlighting the Benefits of Adding Quell Electrical Nerve Stimulation to Outpatient Physical Therapy in Fibromyalgia
- electroCore to Present at the LD Micro Invitational XVI Conference on May 18, 2026
- SEC Form 10-Q filed by electroCore Inc.
Latest ITGR
- Integer to Participate in Truist Securities 2026 MedTech Conference on June 16
- Director Maxwell Martin C was granted 1,967 shares, increasing direct ownership by 9% to 25,106 units (SEC Form 4)
- SEC Form 4 filed by Director Hinrichs James F.
- Director Coyle Michael J was granted 1,967 shares, increasing direct ownership by 145% to 3,322 units (SEC Form 4)
- Director Kapito Aaron was granted 1,967 shares, increasing direct ownership by 144% to 3,338 units (SEC Form 4)
- Director Capps Cheryl C was granted 1,967 shares, increasing direct ownership by 17% to 13,669 units (SEC Form 4)
- Director Jeffers Alvin Tyrone was granted 1,967 shares, increasing direct ownership by 76% to 4,552 units (SEC Form 4)
- Director Antrum Sheila was granted 1,967 shares, increasing direct ownership by 19% to 12,069 units (SEC Form 4)
- Director Passerini Filippo was granted 1,967 shares, increasing direct ownership by 7% to 31,114 units (SEC Form 4)
- Director Flanagan James Francis was granted 1,967 shares, increasing direct ownership by 480% to 2,377 units (SEC Form 4)